Similar articles

• Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.

  Massie BM, Lacourcière Y, Viskoper R, Woittiez A, Kobrin I. Massie BM, et al. Am J Cardiol. 1997 Aug 21;80(4B):27C-33C. doi: 10.1016/s0002-9149(97)00567-5. Am J Cardiol. 1997. PMID: 9286851 Clinical Trial.
• [Mibefradil: a new class calcium inhibitor].

  [No authors listed] [No authors listed] Internist (Berl). 1996 Oct;37(10 Suppl Mibefradil):1-8. Internist (Berl). 1996. PMID: 9402420 German. No abstract available.
• [Evolution of antihypertensive therapy with calcium antagonists: the new molecules].

  Pirrelli A, Vulpis V. Pirrelli A, et al. Cardiologia. 1998 Apr;43(4):357-64. Cardiologia. 1998. PMID: 9659793 Review. Italian. No abstract available.
• [Induction of bradycardia by mibefradil in antihypertensive combination therapy].

  Wagner J, Ritz E. Wagner J, et al. Dtsch Med Wochenschr. 1998 Apr 24;123(17):547. Dtsch Med Wochenschr. 1998. PMID: 9601479 German. No abstract available.
• Use of calcium channel blockers in hypertension.

  Conlin PR, Williams GH. Conlin PR, et al. Adv Intern Med. 1998;43:533-62. Adv Intern Med. 1998. PMID: 9506192 Review.